You could be the one
Call 952-937-9000 to learn more about participating!
Current Clinical Trials
Abbott: Spinal Cord Stimulator (SCS) and Dorsal Root Ganglion (DRG) Systems
- REALITY: Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator: NCT03876054
- PROLONG: Prospective, Multi-center, Open-label, Post-market Study: NCT03908476
- TARGET: A Post-Approval Study to Evaluate Targeted SCS (DRG) Stimulation for the management of Moderate to Severe Chronic, Intractable, Pain of the Lower Limbs due to CRPS Type I and II: NCT02800863
Medtronic: Targeted Drug Delivery Systems and Neurostimulator Systems
- Product Surveillance Registry (PSR) NCT01524276
Survey Says: The Role of Research at Nura
As a national leader in intrathecal pain management therapy, Nura often works with medical device companies to study the long-term performance of specific devices.
An interview with Lisa Haney, Nura’s Director of Research. talks about what draws manufacturers to Nura — and about what they hope to learn.
Device manufacturers are drawn to Nura for two reasons, according to Haney. “Dr. David Schultz is a world-renowned expert in implantable pain management devices. Not only is he published on the topic of interventional pain management, he has the experience as one of the top implanters in the United States.
“In addition, Nura has the numbers — a large patient population — and larger numbers provide variety and ultimately better study data.”
Nura is currently involved in a retrospective chart review study, as well as several post-market device studies for chronic pain management. The latter can last for years, sometimes as long as the devices remain implanted in patients. In addition, the department supports Dr. Schultz’s projects for publication, on topics such as treatment outcomes in the field of chronic pain management
So why conduct research after a device has received FDA approval?
Haney points to three benefits: “First, the real-world, longer-term feedback provided by the research can help improve the next model or iteration. Second, the research can help identify possible new indications for use. And finally, the research data reaffirms the safety and efficacy of the therapy, which is important to manufacturers and insurers, as well as to government regulators.”
Haney, who came to Nura from a device company subsequent to experience at an academic institution and leading consultancies to government agencies such as NIH and DARPA , appreciates the impact research at Nura has. “We help manufacturers understand how their devices perform in real-world conditions,” she noted.
“And when it comes to treating chronic pain, that’s what it’s all about.”